MORRIS, Curly, Christian CHABANNON, Tamas MASSZI, Nigel RUSSELL, Hareth NAHI, Guido KOBBE, Marta KREJČÍ, Holger W. AUNER, David POHLREICH, Patrick HAYDEN, Grzegorz W. BASAK, Stig LENHOFF, Nicolaas SCHAAP, Anja VAN BIEZEN, Cora KNOL, Simona IACOBELLI, Qianying LIU, Marina CELANOVIC, Laurent GARDERET and Nicolaus KROGER. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplantation. London: Nature Publishing Group, 2020, vol. 55, No 2, p. 356-366. ISSN 0268-3369. Available from: https://dx.doi.org/10.1038/s41409-019-0676-0.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Authors MORRIS, Curly (372 Ireland, guarantor), Christian CHABANNON (250 France), Tamas MASSZI (348 Hungary), Nigel RUSSELL (826 United Kingdom of Great Britain and Northern Ireland), Hareth NAHI (752 Sweden), Guido KOBBE (276 Germany), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Holger W. AUNER (826 United Kingdom of Great Britain and Northern Ireland), David POHLREICH (203 Czech Republic), Patrick HAYDEN (372 Ireland), Grzegorz W. BASAK (616 Poland), Stig LENHOFF (752 Sweden), Nicolaas SCHAAP (528 Netherlands), Anja VAN BIEZEN (528 Netherlands), Cora KNOL (528 Netherlands), Simona IACOBELLI (380 Italy), Qianying LIU (840 United States of America), Marina CELANOVIC (840 United States of America), Laurent GARDERET (250 France) and Nicolaus KROGER (276 Germany).
Edition Bone Marrow Transplantation, London, Nature Publishing Group, 2020, 0268-3369.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.483
RIV identification code RIV/00216224:14110/20:00115987
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/s41409-019-0676-0
UT WoS 000511176900012
Keywords in English COLONY-STIMULATING FACTOR; AMERICAN SOCIETY; POOR MOBILIZATION; RISK-FACTORS; BLOOD; TRANSPLANTATION; GUIDELINES; OUTCOMES; CHEMOTHERAPY; COLLECTION
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/7/2020 10:15.
Abstract
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.
PrintDisplayed: 20/7/2024 12:14